Experimental daily GLP-1 pill shows strong blood sugar control in Chinese trial

A new tablet form of a GLP-1 drug has demonstrated meaningful control of blood sugar in people with early type 2 diabetes, according to results from a trial conducted entirely in China. The medication, called safiglipron, reduced HbA1c—a measure of average blood glucose over two to three months—by as much as 1.63 percentage points over 32 weeks. Between 71% and 78% of people taking the drug achieved an HbA1c below 7%, the standard target for diabetes management, compared with just 25% of those given placebo. The findings suggest that oral GLP-1 treatments, which have so far been dominated by injectable formulations, may soon expand into a new category of daily pills.

The OUTSTAND-1 trial enrolled 284 adults across 46 centers in China, all with relatively newly diagnosed type 2 diabetes. Participants had been living with the condition for a median of 1.6 years and were managing it through diet and exercise alone, without medication. They were randomly assigned to receive safiglipron at doses of 30mg, 60mg, or 90mg once daily, or placebo. The highest dose produced the strongest effect: an average HbA1c drop of 1.63 percentage points, while the 30mg and 60mg doses lowered it by 1.40 and 1.38 points respectively. Placebo produced only a 0.18 percentage point reduction. Fasting blood glucose also improved substantially with the 90mg dose, falling by approximately 2.08 mmol/L compared with placebo.

What distinguishes safiglipron from the GLP-1 drugs that have dominated recent treatment advances is its structure and delivery method. It is a small-molecule compound, not a peptide-based drug like semaglutide. This difference matters because small molecules may eventually prove simpler to manufacture and administer than the larger peptide structures. The drug was also designed to work without the fasting and dietary restrictions that complicate some existing oral GLP-1 treatments. As oral Wegovy tablets have only recently become available in the UK, safiglipron represents another potential option in a rapidly expanding landscape of pill-based GLP-1 therapies.

Weight loss accompanied the blood sugar improvements, though it was more modest than what injectable GLP-1 treatments typically produce. People taking the 90mg dose lost an average of 4.78% of their starting body weight, compared with 1.22% for placebo. This pattern suggests safiglipron may ultimately be positioned primarily as a glucose-lowering agent rather than a weight-loss medication, though weight reduction itself remains clinically valuable because it can improve insulin sensitivity and make blood sugar easier to control.

The side-effect profile aligned with what is already known about GLP-1 drugs. Gastrointestinal symptoms, particularly nausea and digestive disturbances, were the most commonly reported adverse events. Treatment discontinuation due to side effects occurred in 1.4% of people taking 30mg, 2.9% taking 60mg, and 6.9% taking 90mg—a pattern that hints at a trade-off between stronger glucose control and tolerability. No one in the placebo group stopped treatment because of adverse effects.

Several important limitations constrain how these results apply beyond the trial population. All participants were recruited in China and had early-stage diabetes, most without prior medication use. The study therefore cannot predict how safiglipron would perform in a broader UK population that includes people with longstanding diabetes, those taking multiple medications, or those with advanced complications. The trial also lasted only 32 weeks, which is too short to establish whether improvements persist over years or whether the drug reduces the risk of cardiovascular disease, kidney disease, or other long-term diabetes complications—questions that require much longer observation.

For people with type 2 diabetes in the UK, there is no immediate change to available treatment options. Safiglipron remains experimental and is not currently licensed in the country. The NHS already offers a range of diabetes medications, and treatment selection depends on individual factors including HbA1c level, cardiovascular risk, kidney function, body weight, and patient preference. What the trial does signal is the direction of the field: oral GLP-1 treatments are developing rapidly, and safiglipron suggests that considerably more pill-based incretin medicines could enter the market in coming years.